Short Description:
CAS number：1264-72-8
Molecular formula：2(C52H98N16O13).5(H2SO4)
molecular weight：2801.27
Chemical structure：
| Basic Information | |
| Product name | Colistin sulfate |
| Grade | Feed Grade |
| Appearance | White or almost white, hygroscopic powder |
| Assay | 99% |
| Shelf life | 2 years |
| Packing | 20kg/carton 20kg/drum |
| Condition | Store at -20℃ for one year（Powder） |
The description of product
Colistin is a cyclic cationic decapeptide linked to a fatty acid side chain, it belongs to a group of similarly structured bacterial antimicrobial peptides. Colistin sulfate is a polypeptide antibiotic which inhibits gram-negative bacteria by binding to lipopolysaccharides and phospholipids in the outer cell membrane of gram-negative bacteria.
Colistin sulfate, also known as colistin sulfate, Christian (Colistin), Polymyxin E(Polymyxin E), antiphytin, white or nearly white powder, odorless, bitter taste moistness, easily soluble in water, slightly soluble in methanol, ethanol, almost insoluble in acetone, ether, free alkali slightly soluble in water. Stable in PH3-7.5 range. Mycolistin sulfate is produced by Bacillus polymyxoides, which has strong antibacterial effect on gram-negative bacteria. It is used to treat intestinal diseases caused by gram-negative bacteria, and is used as a feed additive with obvious growth promoting effect. The combination of sulfadiazine effect is better.
Function of product
Colistin sulfate granules improved in the stability of potency in feed and exhibiting high solubility in spite of their being produced without using any expensive carrier or special equipment. Specifically, colistin sulfate granules consisting essentially of colistin sulfate and having particle diameters of 150 to 1500m, a specific surface area of 40 to 500 cm2/g, a wetting time of 5 minutes or below and a moisture content of 10 % or below.
Pharmacodynamics
Colistin is a polymyxin antibiotic agent. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis.
